EMEA-001624-PIP01-14

Key facts

Active substance
Humanised monoclonal antibody IgG2 recognising the interleukin-31 receptor A (CIM331)
Therapeutic area
Dermatology
Decision number
P/0106/2015
PIP number
EMEA-001624-PIP01-14
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Treatment of atopic dermatitis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Galderma International S.A.S.

E-mail: regulatoryaffairsrx@galderma.com
Tel. +33 1588 64545

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating